Glendon E. French III - 20 May 2021 Form 4/A - Amendment Insider Report for Pulmonx Corp (LUNG)

Role
President and CEO, Director
Signature
/s/ Lauren Cristina, Attorney-in-Fact for Glendon E. French
Issuer symbol
LUNG
Transactions as of
20 May 2021
Net transactions value
-$1,026,780
Form type
4/A - Amendment
Filing time
03 Dec 2021, 18:08:00 UTC
Date Of Original Report
21 May 2021
Previous filing
03 Dec 2021
Next filing
11 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LUNG Common Stock Options Exercise $22,000 +10,000 +0.8% $2.20* 1,259,884 20 May 2021 Direct
transaction LUNG Common Stock Sale $207,470 -5,059 -0.4% $41.01 1,254,825 20 May 2021 Direct F1, F2
transaction LUNG Common Stock Sale $841,311 -19,941 -1.6% $42.19 1,234,884 20 May 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LUNG Stock Option (Right to Buy) Options Exercise $0 -10,000 -5.4% $0.000000 174,999 20 May 2021 Common Stock 10,000 $2.20 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.71 to $41.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.85 to $42.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The shares subject to the option are immediately exercisable and vest in 48 equal monthly installments beginning on August 28, 2020, subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

This amendment is filed to correct the inadvertent omission of the option exercise transaction and the amount of securities beneficially owned following the reported transactions in columns 9 and 5 of each of the reported row in Table II and Table I, respectively. The error in columns 9 and 5 also appears in subsequent Forms 4 filed through November 22, 2021.